A FormBlends network publication
The Science

Sleep apnea: SURMOUNT-OSA and the mechanics of a collapsing airway

Why obesity narrows the upper airway, what the apnea-hypopnea index measures, what tirzepatide did to it in two 52-week trials with and without PAP therapy, and the first FDA approval of a drug for obstructive sleep apnea.

By FormBlends editorial teamUpdated September 4, 2026Educational, not medical advice

Obstructive sleep apnea is a plumbing problem. During sleep the muscles that hold the throat open relax, and if the tube is already narrow and heavy, it collapses. SURMOUNT-OSA tested whether taking weight off the tube reopens it.

The mechanics

Schwartz and colleagues describe the upper airway as a collapsible tube whose behaviour is set by the pressure around it and the muscle tone within it (PubMed 18250211). Fat deposited in the lateral pharyngeal walls, the tongue and the soft palate narrows the lumen and raises the tissue pressure pushing inward. Abdominal fat reduces lung volume, which reduces the downward traction on the trachea that helps hold the pharynx open. The result is a higher critical closing pressure: the airway shuts at a pressure it would otherwise have withstood. Weight loss reverses each of those elements.

The apnea-hypopnea index (AHI) counts complete or partial airway closures per hour of sleep. Five to 15 is mild, 15 to 30 moderate, above 30 severe.

Airway collapsibility in obesity and the AHI results of SURMOUNT-OSALeft: a schematic cross-section of the pharynx showing a narrowed airway lumen surrounded by lateral fat pads, an enlarged tongue base and soft palate, with an arrow from abdominal fat indicating reduced lung volume and less tracheal traction. Labels note that weight loss shrinks the pads and restores traction. Right: bar chart of apnea-hypopnea index change over 52 weeks. Trial 1, no PAP: tirzepatide minus 25.3, placebo minus 5.3. Trial 2, on PAP: tirzepatide minus 29.3, placebo minus 5.5. Weight change is annotated: minus 17.7 versus minus 1.6 percent, and minus 19.6 versus minus 2.3 percent.Why the airway collapsesairway lumenlateral fat padlateral fat padtongue base, soft palate fattissue pressure inwardabdominal fat: lower lung volume,less tracheal traction holding it openWeight loss shrinks the pads and restores tractionAHI change at 52 weeks (events/hour)0-10-20-30-25.3-5.3-29.3-5.5Trial 1: no PAP (n=234)Trial 2: on PAP (n=235)weight -17.7% vs -1.6%weight -19.6% vs -2.3%tirzepatide, max tolerated 10 or 15 mgplacebo
Figure 17. Why the obese airway collapses and what changed in SURMOUNT-OSA. Left: cross-section of the pharynx with the fat depots that narrow it and reduce its support. Right: AHI at baseline and 52 weeks by arm in both trials, drawn to the reported means. Sources: Schwartz 2008; Malhotra 2024.

The trials

SURMOUNT-OSA was two parallel 52-week trials in adults with moderate to severe obstructive sleep apnea and obesity, 469 participants in total. Trial 1 enrolled people not using positive airway pressure therapy; trial 2 enrolled people already on PAP, who continued it. Tirzepatide was escalated to the maximum tolerated dose of 10 or 15 mg.

In trial 1, AHI fell by 25.3 events per hour on tirzepatide versus 5.3 on placebo, a difference of -20.0 (95% CI -25.8 to -14.2). In trial 2, it fell by 29.3 versus 5.5, difference -23.8 (95% CI -29.6 to -17.9). Weight fell 17.7% versus 1.6% in trial 1 and 19.6% versus 2.3% in trial 2. Secondary endpoints, including hypoxic burden, sleepiness scores, systolic blood pressure and C-reactive protein, improved as well (PubMed 38912654). Adverse events were the gastrointestinal profile familiar from the SURMOUNT programme.

On December 20, 2024 FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, the first drug approval for the condition. The Zepbound label carries the indication alongside the weight-management one.

What the result does and does not show

It shows that a large, sustained weight loss reduces airway collapse events by roughly two thirds on average, whether or not PAP is in use. It does not show that everyone reaches a normal AHI: the group means moved from severe into the moderate range, and individual results spread widely. It does not show a receptor effect on the airway; nothing in the mechanism requires one, and none has been demonstrated. And it does not show what happens to AHI if the drug is stopped and weight returns, although the physiology on the why weight returns page makes the direction predictable.

Compounded tirzepatide is not FDA approved for this or any indication and was not the product studied.

Where to go next

Questions people ask

Is this a direct effect on the airway or just weight loss?

Almost certainly weight loss, acting on the fat around and inside the pharynx and on lung volume. Weight fell 17.7% and 19.6% in the two trials, and the AHI reduction tracked it. No receptor-mediated effect on airway muscle has been shown. The trials did not include a weight-matched comparator, so a small independent contribution cannot be excluded, but none is needed to explain the result.

Does this replace CPAP?

The trials do not say that. Trial 2 enrolled people already using PAP and they continued it. Many participants still had residual apnea at 52 weeks. Whether to change PAP use is a decision for a sleep clinician with a repeat sleep study, not something to infer from a group mean.

Sources

  1. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med 2024. PubMed 38912654 Accessed September 4, 2026.
  2. Schwartz AR, Patil SP, Laffan AM, et al. Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches. Proc Am Thorac Soc 2008. PubMed 18250211 Accessed September 4, 2026.
  3. Zepbound (tirzepatide) prescribing information. Drugs@FDA, NDA 217806 Accessed September 4, 2026.

Canonical URL: https://formblendsscience.com/outcomes/sleep-apnea-surmount-osa. Written by the FormBlends editorial team. This page is educational and is not medical advice; see the medical disclaimer.